secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2023-10-23T23:59:59+00:00
Accession:  0001104659-23-110653
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech secures $10M revolving credit facility from CEO; $3.5M available, matures March 2026
--------------------------------------------------------------------------------

- Revolving credit facility of up to $10M from Pardeep Nijhawan Medicine Professional Corp., controlled by CEO.
- Initial credit limit of $3.5M; facility matures March 31, 2026 unless terminated by 90 days' notice.
- Interest at CIBC US Base Rate plus 3% per annum; monthly standby fee of 1.5% on unused portion.
- Repayment due within 5 business days of receiving funds from Canada's Strategic Innovation Fund (SIF).
- Borrowing base tied to eligible SIF grant and license fee receivables; 85% advance rate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000110465923110653/0001104659-23-110653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000110465923110653/tm2328896d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-110653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer